- Home
- MCS vs REPL Comparison
MCS vs REPL Comparison
Compare MCS & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCS
- REPL
- Stock Information
- Founded
- MCS 1935
- REPL 2015
- Country
- MCS United States
- REPL United States
- Employees
- MCS 7780
- REPL 331
- Industry
- MCS Movies/Entertainment
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MCS Consumer Discretionary
- REPL Health Care
- Exchange
- MCS Nasdaq
- REPL Nasdaq
- Market Cap
- MCS 658.0M
- REPL 1.1B
- IPO Year
- MCS N/A
- REPL 2018
- Fundamental
- Price
- MCS $20.91
- REPL $13.98
- Analyst Decision
- MCS Strong Buy
- REPL Strong Buy
- Analyst Count
- MCS 3
- REPL 6
- Target Price
- MCS $23.00
- REPL $19.83
- AVG Volume (30 Days)
- MCS 156.3K
- REPL 610.9K
- Earning Date
- MCS 02-27-2025
- REPL 02-12-2025
- Dividend Yield
- MCS 1.30%
- REPL N/A
- EPS Growth
- MCS N/A
- REPL N/A
- EPS
- MCS N/A
- REPL N/A
- Revenue
- MCS $670,229,000.00
- REPL N/A
- Revenue This Year
- MCS $6.18
- REPL N/A
- Revenue Next Year
- MCS $5.98
- REPL $1,065.54
- P/E Ratio
- MCS N/A
- REPL N/A
- Revenue Growth
- MCS N/A
- REPL N/A
- 52 Week Low
- MCS $9.56
- REPL $4.92
- 52 Week High
- MCS $23.16
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MCS 46.22
- REPL 55.54
- Support Level
- MCS $20.85
- REPL $13.40
- Resistance Level
- MCS $22.38
- REPL $14.59
- Average True Range (ATR)
- MCS 0.60
- REPL 0.84
- MACD
- MCS 0.01
- REPL -0.02
- Stochastic Oscillator
- MCS 42.13
- REPL 66.52
About MCS Marcus Corporation (The)
Marcus Corp is engaged in two business segments, which are Theatres and Hotels and Resorts. The Theatre segment operates multiscreen motion picture theatres in Wisconsin, Illinois, Iowa, Minnesota, Missouri, Nebraska, North Dakota, Ohio ands others, a family entertainment center in Wisconsin and a retail center in Missouri; Hotels and Resorts segment owns and operates full-service hotels and resorts in Wisconsin, Illinois, and Nebraska and manages full-service hotels, resorts and other properties in Wisconsin, Minnesota, Texas, Nevada, California, and North Carolina. It generates maximum revenue from the Theatres segment.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.